Book of the Month
How much does this monthly book subscription actually cost?
Ozempic, Wegovy, and Other GLP-1 RA Medications
Multiple class-action lawsuits regarding the marketing of GLP-1 RAs were transferred to be heard together as part of multidistrict litigation (MDL). More information on the MDL is below.
Case Name (Date)
In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
24-md-3094, E.D. Penn.
(2024)
Product/Service
Ozempic, Wegovy, Rybelsus, Saxenda, Victoza, Mounjaro, Zepbound, Trulicity and other GLP-1 RA medications
Allegations
Marketing products as weight-loss medications without adequately disclosing that many people stop using them due to their side effects, the medications do not result in meaningful weight loss for up to 15 percent of people, the average weight loss is approximately 10 percent of a person’s body weight, and people need to stay on them to maintain their weight loss
Status
Pending
The Latest
TINA.org Supports FTC’s ‘Click to Cancel’ Rule against Industry Challenge
Companies should not be able to trap consumers into subscriptions that they do not want.
Rolling Stone Subscriptions
Getting out may not be as easy as signing up.
Menopause Is the Worst. These Everyday Tools Can Help.
Ellen Lee, The New York Times
Obvi
TINA.org discovers the evidence behind these weight-loss claims is slim.